BRCA1在乳腺浸润性导管癌中的表达及其与Ki-67、p53的关系

目的：观察乳腺浸润性导管癌组织中BRCA1、Ki-67及p53的表达及其与临床病理特征之间的关系。方法采用EliVisionTMplus两步免疫组化方法，检测BRCA1、Ki-67及P53在60例乳腺浸润性导管癌组织的表达情况。结果①60例乳腺浸润性导管癌组织中，BRCA1的阳性率为60．0％（36／60），Ki-67及 p53的阳性率分别为56．67％（34／60）、48．33％（29／60）；②BRCA1蛋白表达与患者发病年龄、临床分期、伴有腋淋巴结转移以及组织学分级有关（P＜0．05），而与肿瘤大小无关（P＞0．05）；Ki-67表达与临床分期、淋巴结转移、组织学分级有关（P＜0．05），与发病年龄、肿瘤大小无关（P＞0．05）；p53表达与肿瘤大小、临床分期、淋巴结转移、组织学分级相关（P＜0．05），与发病年龄无关（P＞0．05）；③BRCA1表达与 Ki-67、p53均呈负相关（r1＝－0．577，P＜0．05，r2＝－0．504，P ＜0．05），Ki-67与p53的表达呈正相关（r ＝0．375，P＜0．05）。结论联合检测BRCA1、Ki-67及p53对乳腺癌的早期诊断、恶性程度判定和预后监测有重要意义，可为乳腺癌的个体化治疗提供有效的指针。

Expression of BRCA1 in invasive ductal carcinoma and its correlation with Ki-67 and p53

Objective ToinvestigatetheexpressionsofBRCA1,Ki-67andp53proteinininva-siveductalcarcinomaanddiscusstheircorrelationswithclinicopathologicalfeatures.Methods Theex-pressions of BRCA1,Ki-67and p53 were detected by immunohistochemistry with EliVisionTMplus two-step methodin60samplesofinvasiveductalcarcinomatissue.Results ThepositiverateofBRCA1protein was 60.0%（36/60）.The positive rates of Ki-67 and p53 were 56.67%（34/60）and 48.33%（29/60）. The expression of BRCA1 protein was related to the age of onset,clinical stage,lymph node metastasis and histological grade（P〈0.05）,but not associated with tumor size（P〉0.05）.The expression of Ki-67 was related to the clinical stage,lymph node metastasis and histological grade（P〈0.05）,but not associated with the age of onset or tumor size（P〉0.05）.The expression of p53 was related to the age of onset,clini-cal stage,lymph node metastasis and histological grade（P〈0.05）,but not associated with tumor size（P〉0.05）.The expression of BRCA1 protein in invasive ductal carcinoma was negatively correlated with Ki-67 and p53（r1 =-0.577,P〈0.05,r2 =-0.504,P〈0.05）.The expression of Ki-67 was positively corre-latedwithp53（r=0.375,P〈0.05）.Conclusion CombineddetectionofBRCA1,Ki-67andp53isof important significance in early diagnosis,malignancy judgment and prognosis monitoring for invasive ductal carcinoma,which can provide effective indexes for individualized therapies.